Novel LHRH-receptor-targeted cytolytic peptide, EP-100: First-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors

Kelly K. Curtis, John Sarantopoulos, Donald W Northfelt, Glen J. Weiss, Kerry M. Barnhart, John K. Whisnant, Carola Leuschner, Hector Alila, Mitesh J Borad, Ramesk K Ramanathan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: To conduct a phase I study determining the safety, pharmacokinetics and preliminary efficacy of EP-100, a novel anticancer drug consisting of natural luteinizing-hormone-releasing hormone (LHRH) ligand linked to a cationic membrane-disrupting peptide. Methods: Patients with advanced, solid tumors, positive for LHRH receptor by immunohistochemistry (IHC), received EP-100 weekly or twice weekly for 3 of 4 weeks in a 28 day cycle. A modified Fibonacci 3 + 3 dose-escalation schema was used. Initial cohorts received EP-100 once weekly (cohorts 1-7, 0.6-7.8 mg/m2, n = 21). Later cohorts received doses twice weekly (cohorts 7-11, 7.8-40 mg/m2, n = 16). Results: LHRH-receptor expression was confirmed by IHC in 52 of 89 consented patients; 37 patients received at least 1 dose. Cohorts receiving doses of 5.2 mg/m2 and above achieved therapeutic levels from in vitro studies Clearance was rapid (mean half-life 7.1 ± 3.8 to 15.9 ± 3.6 min). The maximum-tolerated dose was not reached at the highest dose evaluated (40 mg/m2 twice weekly). Grade 2 increase in alanine aminotransferase/ serum aspartate aminotransferase in one patient resolved, did not recur upon re-treatment, and was not observed in other patients. The only drug-related adverse event was transient infusion-related dermatologic reactions (10 patients). No complete or partial tumor responses were observed; seven patients had stable disease of 16 weeks. Conclusions: EP-100 was well tolerated in patients with advanced, LHRH-receptor-expressing solid tumors. The recommended phase 2 dose is 40 mg/m2 twice weekly for 3 of 4 weeks per cycle.

Original languageEnglish (US)
Pages (from-to)931-941
Number of pages11
JournalCancer Chemotherapy and Pharmacology
Volume73
Issue number5
DOIs
StatePublished - 2014

Fingerprint

LHRH Receptors
Tumors
Peptides
Neoplasms
Pharmacokinetics
Aspartate Aminotransferases
Alanine Transaminase
Gonadotropin-Releasing Hormone
Pharmaceutical Preparations
Ligands
Membranes
Immunohistochemistry
Maximum Tolerated Dose
Drug-Related Side Effects and Adverse Reactions
Half-Life
Safety

Keywords

  • Advanced/metastatic solid tumors
  • Cytolytic peptide
  • Cytolytic peptide conjugate
  • EP-100
  • LHRH receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Novel LHRH-receptor-targeted cytolytic peptide, EP-100 : First-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. / Curtis, Kelly K.; Sarantopoulos, John; Northfelt, Donald W; Weiss, Glen J.; Barnhart, Kerry M.; Whisnant, John K.; Leuschner, Carola; Alila, Hector; Borad, Mitesh J; Ramanathan, Ramesk K.

In: Cancer Chemotherapy and Pharmacology, Vol. 73, No. 5, 2014, p. 931-941.

Research output: Contribution to journalArticle

Curtis, Kelly K. ; Sarantopoulos, John ; Northfelt, Donald W ; Weiss, Glen J. ; Barnhart, Kerry M. ; Whisnant, John K. ; Leuschner, Carola ; Alila, Hector ; Borad, Mitesh J ; Ramanathan, Ramesk K. / Novel LHRH-receptor-targeted cytolytic peptide, EP-100 : First-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. In: Cancer Chemotherapy and Pharmacology. 2014 ; Vol. 73, No. 5. pp. 931-941.
@article{7d2da8c3e655440cb046936edc3437ea,
title = "Novel LHRH-receptor-targeted cytolytic peptide, EP-100: First-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors",
abstract = "Purpose: To conduct a phase I study determining the safety, pharmacokinetics and preliminary efficacy of EP-100, a novel anticancer drug consisting of natural luteinizing-hormone-releasing hormone (LHRH) ligand linked to a cationic membrane-disrupting peptide. Methods: Patients with advanced, solid tumors, positive for LHRH receptor by immunohistochemistry (IHC), received EP-100 weekly or twice weekly for 3 of 4 weeks in a 28 day cycle. A modified Fibonacci 3 + 3 dose-escalation schema was used. Initial cohorts received EP-100 once weekly (cohorts 1-7, 0.6-7.8 mg/m2, n = 21). Later cohorts received doses twice weekly (cohorts 7-11, 7.8-40 mg/m2, n = 16). Results: LHRH-receptor expression was confirmed by IHC in 52 of 89 consented patients; 37 patients received at least 1 dose. Cohorts receiving doses of 5.2 mg/m2 and above achieved therapeutic levels from in vitro studies Clearance was rapid (mean half-life 7.1 ± 3.8 to 15.9 ± 3.6 min). The maximum-tolerated dose was not reached at the highest dose evaluated (40 mg/m2 twice weekly). Grade 2 increase in alanine aminotransferase/ serum aspartate aminotransferase in one patient resolved, did not recur upon re-treatment, and was not observed in other patients. The only drug-related adverse event was transient infusion-related dermatologic reactions (10 patients). No complete or partial tumor responses were observed; seven patients had stable disease of 16 weeks. Conclusions: EP-100 was well tolerated in patients with advanced, LHRH-receptor-expressing solid tumors. The recommended phase 2 dose is 40 mg/m2 twice weekly for 3 of 4 weeks per cycle.",
keywords = "Advanced/metastatic solid tumors, Cytolytic peptide, Cytolytic peptide conjugate, EP-100, LHRH receptor",
author = "Curtis, {Kelly K.} and John Sarantopoulos and Northfelt, {Donald W} and Weiss, {Glen J.} and Barnhart, {Kerry M.} and Whisnant, {John K.} and Carola Leuschner and Hector Alila and Borad, {Mitesh J} and Ramanathan, {Ramesk K}",
year = "2014",
doi = "10.1007/s00280-014-2424-x",
language = "English (US)",
volume = "73",
pages = "931--941",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Novel LHRH-receptor-targeted cytolytic peptide, EP-100

T2 - First-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors

AU - Curtis, Kelly K.

AU - Sarantopoulos, John

AU - Northfelt, Donald W

AU - Weiss, Glen J.

AU - Barnhart, Kerry M.

AU - Whisnant, John K.

AU - Leuschner, Carola

AU - Alila, Hector

AU - Borad, Mitesh J

AU - Ramanathan, Ramesk K

PY - 2014

Y1 - 2014

N2 - Purpose: To conduct a phase I study determining the safety, pharmacokinetics and preliminary efficacy of EP-100, a novel anticancer drug consisting of natural luteinizing-hormone-releasing hormone (LHRH) ligand linked to a cationic membrane-disrupting peptide. Methods: Patients with advanced, solid tumors, positive for LHRH receptor by immunohistochemistry (IHC), received EP-100 weekly or twice weekly for 3 of 4 weeks in a 28 day cycle. A modified Fibonacci 3 + 3 dose-escalation schema was used. Initial cohorts received EP-100 once weekly (cohorts 1-7, 0.6-7.8 mg/m2, n = 21). Later cohorts received doses twice weekly (cohorts 7-11, 7.8-40 mg/m2, n = 16). Results: LHRH-receptor expression was confirmed by IHC in 52 of 89 consented patients; 37 patients received at least 1 dose. Cohorts receiving doses of 5.2 mg/m2 and above achieved therapeutic levels from in vitro studies Clearance was rapid (mean half-life 7.1 ± 3.8 to 15.9 ± 3.6 min). The maximum-tolerated dose was not reached at the highest dose evaluated (40 mg/m2 twice weekly). Grade 2 increase in alanine aminotransferase/ serum aspartate aminotransferase in one patient resolved, did not recur upon re-treatment, and was not observed in other patients. The only drug-related adverse event was transient infusion-related dermatologic reactions (10 patients). No complete or partial tumor responses were observed; seven patients had stable disease of 16 weeks. Conclusions: EP-100 was well tolerated in patients with advanced, LHRH-receptor-expressing solid tumors. The recommended phase 2 dose is 40 mg/m2 twice weekly for 3 of 4 weeks per cycle.

AB - Purpose: To conduct a phase I study determining the safety, pharmacokinetics and preliminary efficacy of EP-100, a novel anticancer drug consisting of natural luteinizing-hormone-releasing hormone (LHRH) ligand linked to a cationic membrane-disrupting peptide. Methods: Patients with advanced, solid tumors, positive for LHRH receptor by immunohistochemistry (IHC), received EP-100 weekly or twice weekly for 3 of 4 weeks in a 28 day cycle. A modified Fibonacci 3 + 3 dose-escalation schema was used. Initial cohorts received EP-100 once weekly (cohorts 1-7, 0.6-7.8 mg/m2, n = 21). Later cohorts received doses twice weekly (cohorts 7-11, 7.8-40 mg/m2, n = 16). Results: LHRH-receptor expression was confirmed by IHC in 52 of 89 consented patients; 37 patients received at least 1 dose. Cohorts receiving doses of 5.2 mg/m2 and above achieved therapeutic levels from in vitro studies Clearance was rapid (mean half-life 7.1 ± 3.8 to 15.9 ± 3.6 min). The maximum-tolerated dose was not reached at the highest dose evaluated (40 mg/m2 twice weekly). Grade 2 increase in alanine aminotransferase/ serum aspartate aminotransferase in one patient resolved, did not recur upon re-treatment, and was not observed in other patients. The only drug-related adverse event was transient infusion-related dermatologic reactions (10 patients). No complete or partial tumor responses were observed; seven patients had stable disease of 16 weeks. Conclusions: EP-100 was well tolerated in patients with advanced, LHRH-receptor-expressing solid tumors. The recommended phase 2 dose is 40 mg/m2 twice weekly for 3 of 4 weeks per cycle.

KW - Advanced/metastatic solid tumors

KW - Cytolytic peptide

KW - Cytolytic peptide conjugate

KW - EP-100

KW - LHRH receptor

UR - http://www.scopus.com/inward/record.url?scp=84900825798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900825798&partnerID=8YFLogxK

U2 - 10.1007/s00280-014-2424-x

DO - 10.1007/s00280-014-2424-x

M3 - Article

C2 - 24610297

AN - SCOPUS:84900825798

VL - 73

SP - 931

EP - 941

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -